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Abstract
Introduction: Recent evidence suggests that vitamin D plays a role in pathogenesis of arterial hypertension. The aim 
was to assess vitamin D in children and adolescents with arterial hypertension.
Material and methods: In 49 children (14.29 ± 3.17 years) with arterial hypertension we evaluated vitamin D 
status (according to Polish 2018 Guidelines), serum calcium, phosphorus, parathormone, alkaline phosphatase, 
office blood pressure, ABPM (including ambulatory arterial stiffness index [AASI]), BMI, GFR, uric acid, lipids and 
albuminuria. None of the children were supplemented with vitamin D. 
Results: Mean vitamin D concentration was 19.74 ± 9.68 ng/mL. Vitamin D severe deficiency (0–10 ng/mL) was 
found in 5 (10.2%), deficiency (> 10–20 ng/mL) in 29 (49.0%), suboptimal concentration (> 20–30 ng/mL) in 17 
(34.7%), optimal concentration (> 30 to 50 ng/mL) in 1 (2.0%), and high concentration (> 50 to 100 ng/mL) in  
2 (4.1%) children. Vitamin D was higher in spring-summer vs. autumn-winter (21.79 ± 10.19 vs. 15.53 ± 7.08 ng/mL,  
p = 0.03). Vitamin D correlated with height Z-score (r = 0.39, p < 0.01), BMI Z-score (r = –0.34, p = 0.02), uric 
acid (r = -0.31, p = 0.04), triglycerides (r = -0.37, p = 0.01), but not with office blood pressure and ABPM parame-
ters except for heart rate (r = -0.38, p < 0.01). In 24 children treated with antihypertensive medications vitamin D 
correlated with AASI (r = 0.50, p = 0.04).
Conclusions: 
1. Inadequate vitamin D supply is ubiquitous in children with arterial hypertension.
2. Vitamin D deficiency should be suspected especially in autumn-winter period and among obese and short chil-
dren.
3. The relation between vitamin D status and ambulatory arterial stiffness index suggests negative influence of vita-
min D on arterial wall but requires further investigations.
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Introduction
Arterial hypertension (AH) is found in 3–5% of 
children and adolescents. Primary hypertension (PH) 
is a dominant form of AH in teenagers and its prev-
alence in paediatric population is increasing due to 
outbreak of obesity and excessive salt intake [1, 2].
Twenty-four hour ambulatory blood pressure 
monitoring (ABPM) allows earlier detection of ab-
normal blood pressure and shows better correlation 
with target organ damage compared to office mea-
surements. High blood pressure variability and dis-
turbed circadian blood pressure rhythm were found 
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to be risk factors for the development of target organ 
damage including left ventricular hypertrophy [3]. 
Based on ABPM data [4], the ambulatory arterial 
stiffness index (AASI) was proposed as a marker of 
arterial compliance. 
Vitamin D is a group of fat-soluble sterols with 
most important compounds being vitamin D3 (chole-
calciferol) and vitamin D2 (ergocalciferol). Ingest-
ed vitamin D is hydroxylated in liver to calcifediol 
(25(OH)D), which is the most abundant metabolite 
of vitamin D, and its serum concentration defines 
the status of vitamin D supply. Calcifediol is further 
hydroxylated by kidneys to calcitriol (1,25(OH)2D), 
the biologically active form of vitamin D [5, 6]. 
Vitamin D deficiency affects general population 
irrespective of latitude, age, sex and race [5]. In 
Poland vitamin D deficiency was found in 90% 
of adults, children and adolescents [7, 8]. Vitamin 
D deficiency may be associated with well-known 
calcaemic effects as well as with a broad spectrum 
of other effects, e.g. increased risk of neoplasms, 
asthma, autoimmune disorders and cardiovascular 
diseases [5, 6]. 
The relation between vitamin D status and risk of 
arterial hypertension has been thoroughly studied in 
recent years [9–14]. Experimental studies indicate 
that vitamin D deficiency may contribute to blood 
pressure elevation by activation of renin-angioten-
sin-aldosterone system, generation of reactive oxygen 
species with resulting endothelial dysfunction and 
impaired secretion of nitric oxide [6, 15].
In observational studies an inverse relation be-
tween vitamin D status and arterial hypertension 
was found [11–14] but interventional trials have not 
confirmed unequivocally the impact of vitamin D 
supplementation on reducing blood pressure [9].
There are only single studies on vitamin D in 
paediatric patients with hypertension. Płudowski did 
not find significant differences in vitamin D status 
between children with prehypertension, hyperten-
sion stage 1, and stage 2. Also these authors [16] 
did not find relation between vitamin D supply and 
carotid intima media thickness and left ventricular 
mass. Kao [17] found that vitamin D status is in-
versely related to systolic and diastolic blood pressure 
in overweight and obese adolescents.
To the best of our knowledge there are no data on 
relation between vitamin D status and blood pres-
sure evaluated by ABPM and ABPM-derived indices 
(blood pressure dipping, blood pressure variability, 
ambulatory arterial stiffness index).
The aim of our study was to assess vitamin D 
status in children and adolescents with primary hy-
pertension and to find relations between vitamin 
D, blood pressure assessed in office measurement 
and ABPM, and selected clinical and biochemical 
parameters.
Material and methods
In this prospective cross-sectional single-centre study 
we analysed data of 49 children and adolescents with 
primary hypertension. Children who were supple-
mented with vitamin D during last 12 months were 
excluded from the study.
In all children hypertension was confirmed using 
Polish Society of Arterial Hypertension and Polish 
Society of Paediatric Nephrology guidelines [1, 2]. 
Secondary forms of hypertension were excluded 
by medical history and physical examination and 
by means of additional tests: renal function tests 
(creatinine, urea), serum ions (sodium, potassium, 
and calcium), capillary blood gases, urinalysis, and 
abdominal ultrasonography with evaluation of kid-
neys, urinary tract, adrenal glands, and blood flow in 
renal arteries. Detailed diagnostic tests for secondary 
forms of hypertension were performed in all children 
younger than 10 years and with grade II hyperten-
sion [1, 2].
In all patients we assessed following clinical pa-
rameters: sex, age [years], duration of arterial hyper-
tension [months], height [cm], weight [kg], BMI 
[kg/m2]. Anthropometric variables were compared 
with Polish normative data and expressed as Z-score 
[18]. Overweight and obesity were defined according 
to World Health Organization definitions as BMI 
Z-score values > 1 and > 2, respectively. We assessed 
also antihypertensive medications and time period 
(month) of clinical and biochemical evaluation.
Following biochemical parameters were evaluat-
ed: serum creatinine [mg/dL], uric acid [mg/dL], 
total cholesterol [mg/dL], triglycerides [mg/dL], and 
daily urinary albumin loss [mg/24h]. Glomerular 
filtration rate (GFR) was calculated according to 
Schwartz formula [19]. Hyperuricaemia was defined 
as uric acid > 6.0 mg/dL, hypercholesterolaemia as 
cholesterol ≥ 200 mg/dL, hypertriglyceridaemia as 
triglycerides ≥ 100 mg/dL (children aged 0–9 years) 
or ≥ 130 mg/dL (children aged 10–19 years), and 
abnormal urinary albumin excretion as albuminuria 
> 30 mg/24h [1, 2]. 
Following parameters of calcium-phosphorus me-
tabolism were evaluated: 25(OH)D [ng/mL], cal cium 
[mg/dL], inorganic phosphorus [mg/dL], alkaline 
phosphatase [IU/L], and intact parathormone (PTH) 
[pg/mL]. According to Polish recommendations, 
vitamin D concentrations were defined as: severe 
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deficiency (0–10 ng/mL), deficiency (> 10–20 ng/ 
/mL), suboptimal (> 20–30 ng/mL), optimal 
(> 30–50 ng/mL), high (> 50–100 ng/mL), and toxic 
(> 100 ng/mL) levels [5]. Normal concentrations of 
calcium (8.8–10.7 mg/dL), phosphorus (2.8–5.6 mg/ 
/dL), alkaline phosphatase (45–515 IU/L), and 
parathormone (12–95 pg/mL) were taken from nor-
mative values in accordance with producer’s recom-
mendations. Vitamin D was assessed by chemilumi-
nescence (ARCHITECT i1000SR, Abbott, USA), 
parathormone by chemiluminescence (IMMULITE 
2000XPi, Healthcare-in-Europe, Germany), all other 
biochemical parameters by dry chemistry (VITROS 
5600, Ortho Clinical Diagnostics, USA). 
Peripheral blood pressure was measured using os-
cillometric device (Welch Allyn VSM Patient Mon-
itor 300, Welch Allyn, USA). Obtained values were 
expressed as [mm Hg] and were compared with nor-
mative values [20] and expressed as Z-score. 
24-hour blood pressure measurement was per-
formed using a SUNTECH OSCAR 2 device (Sun-
Tech Medical, Inc., Morrisville, NC, USA) and in-
terpreted according to the American Heart Associa-
tion (AHA) guidelines. Monitors were programmed 
to measure blood pressure every 15 minutes from 
6 AM to 10 PM and every 30 minutes from 10 PM 
to 6 AM. Periods of night-time rest and daytime 
activity were determined individually by providing 
data in a diary. Following parameters were evaluat-
ed based on ABPM: systolic, diastolic, and mean 
arterial pressure (SBP, DBP, MAP) during 24 hours 
[mm Hg], systolic and diastolic blood pressure load 
during 24 hours [%], nocturnal blood pressure dip 
[%], blood pressure variability, and AASI. Blood 
pressure load was calculated as a percentage of mea-
surements ≥ 95th percentile during 24 hours and 
increased load was defined as > 25% [3]. AASI 
was calculated as 1 minus correlation coefficient 
between diastolic and systolic blood pressure values 
over 24 hours in ABPM [4]. Nocturnal systolic and 
diastolic blood pressure dip (SBP DIP, DBP DIP, 
respectively) was calculated as difference between 
daytime pressure and nighttime pressure expressed 
as a percentage of the day value. Disturbed circadi-
an blood pressure rhythm was defined as nocturnal 
systolic or diastolic blood pressure dip less than 
10%. Blood pressure variability was calculated as 
standard deviation (SD) from mean of all systolic 
or diastolic blood pressure values over 24 hours (SD 
SBP/24h, SD DBP/24h) [3].
The research project was approved by local Eth-
ics Committee (approval No. KB/58/2016). All 
procedures were performed in accordance with the 
Declaration of Helsinki on the treatment of human 
subjects. Informed consent was obtained from all 
participants (≥ 16 years) and their representatives 
included in the study.
Statistical analysis
Statistical elaboration was performed using Dell 
Statistica 13.0 PL software (Dell Inc., AlisoViejo, 
CA, USA). Variables were presented as the mean 
± standard deviation (SD). Normality of data dis-
tribution was tested using the Shapiro-Wilk test. 
Differences between normally distributed data were 
tested using the Student t-test, whereas differences 
between non-normally distributed data using the 
U Mann-Whitney test. Correlations between para-
metric and non-parametric variables were evaluated 
using the Pearson or the Spearman rank correlation, 
respectively. A p-value < 0.05 was considered statis-
tically significant.
Results
Clinical characteristics of the study group together 
with biochemical parameters were presented in Table I. 
In the study group, about two third of the patients 
were boys. Mean age of the studied children was 
about 14 years; 5 (10.2%) children were younger 
than 10 years. Twenty-nine (59.2%) patients were 
Table I. Clinical and biochemical characteristics of the study 
group
Parameter Value
Number of patients (n) 49 
Boys/girls (n, %) 34/15 (69.4%/30.6%)
Age [years] 14.29 ± 3.17  
(from 5.58 to 18.0)
Duration of arterial hypertension [months] 19.26 ± 20.52
BMI Z-score 1.19 ± 0.79
Overweight (n, %) 14 (28.6%)
Obesity (n, %) 15 (30.6%)
Antihypertensive medications (n, %) 24 (49.0%)
Number of antihypertensive medications:
    1 medication
    2 medications
    3 medications
14
9
1
GFR ac. to Schwartz [mL/min/1.73 m2] 99.41 ± 20.95
Total cholesterol [mg/dL] 163.86 ± 37.46
Triglycerides [mg/dL] 94.19 ± 32.42
Uric acid [mg/dL] 5.53 ± 1.23
Albumin urinary excretion [mg/24h] 23.68 ± 31.54
BMI — body mass index; GFR — glomerular filtration rate
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Table II. Parameters of calcium-phosphorus metabolism in children and adolescents with primary hypertension
Parameter Value
Calcium [mg/dL] 9.99 ± 0.27
Phosphorus [mg/dL] 4.54 ± 0.68
Calcium phosphorus product [mg2/dL2] 45.22 ± 7.04
Parathormone [pg/mL] 19.74 ± 9.68
Alkaline phosphatase [IU/L] 126.73 ± 61.44
25(OH)D [ng/mL] 19.74 ± 9.68 (from 6.1 to 55.3)
Vit. D severe deficiency (25(OH)D: 0–10 ng/mL) 5 (10.2%)
Vit. D deficiency (25(OH)D: < 20 ng/mL) 29 (49.0%)
Vit. D suboptimal status (25(OH)D: 20–30 ng/mL) 17 (34.7%)
Vit. D optimal status (25(OH)D: >30–50 ng/mL) 1 (2.0%)
Vit. D high supply (25(OH)D: > 50–100 ng/mL) 2 (4.1%)
Table III. Blood pressure measurements in the studied children
Office blood pressure
Systolic blood pressure [mm Hg]
Systolic blood pressure Z-score
136.04 ± 13.76
2.14 ± 0.98
Diastolic blood pressure [mm Hg]
Diastolic blood pressure Z-score
81.47 ± 9.98
1.38 ± 0.79
24-hour ambulatory blood pressure monitoring
Systolic blood pressure during 24h [mm Hg] 130.82 ± 10.72
Diastolic blood pressure during 24h [mm Hg] 71.88 ± 6.85
Mean blood pressure during 24h [mm Hg] 91.51 ± 7.51
Mean blood pressure during 24h Z-score 1.49 ± 1.32
SBP load during 24h [%] 47.08 ± 22.02
DBP load during 24h [%] 26.96 ± 19.88
SBP variability 13.44 ± 2.64
DBP variability 11.32 ± 2.56
SBP dipping [%] 11.68 ± 5.75
DBP dipping [%] 17.78 ± 7.45
Ambulatory arterial stiffness index 0.38 ± 0.12
SBP — systolic blood pressure; DBP — diastolic blood pressure
overweight or obese. Half of the patients were already 
treated with antihypertensive medications during the 
evaluation. All children had normal kidney function. 
Hyperuricaemia was recognized in 13 (26.5%) patients 
with highest uric acid concentration 8.2 mg/dL. Hyper-
cholesterolaemia was found in 6 (12.2%), and hypertri-
glyceridaemia in 7 (14.3%) children. Elevated urinary 
albumin excretion was found in 8 (16.3%) patients.
Parameters of calcium-phosphorus metabolism 
were presented in Table II. In all the studied children 
calcium, phosphorus, calcium-phosphorus product, 
alkaline phosphatase, as well as intact parathormone 
were within normal limits. Vitamin D deficiency and 
suboptimal concentration were revealed in 46 out of 
49 patients (93.9%).
Blood pressure measurements were presented in 
Table III. In 24-hour ABPM performed at the day 
of blood sampling, systolic hypertension was found 
in 34 patients (69.4%), and diastolic hypertension 
in 12 children (24.9%); 21 patients (42.9%) had 
elevated mean arterial pressure. Abnormal systolic, 
diastolic or mean blood pressure was found in all 25 
children with untreated arterial hypertension. Dis-
turbed circadian blood pressure rhythm was found 
in 16 children (32.7%). 
Vitamin D concentration was significantly higher 
in spring-summer period compared to autumn-win-
ter period (21.79 ± 10.19 vs. 15.53 ± 7.08 ng/mL, 
p = 0.03). We found no differences in vitamin D 
concentration between boys and girls (20.14 ± 11.13 
vs. 18.83 ± 5.25 ng/mL, p = 0.97) and between chil-
dren treated and not treated with antihypertensive 
medications (20.72 ± 12.71 vs. 18.80 ± 5.53 ng/mL, 
p = 0.65) (Figure 1). 
In group of 49 children vitamin D concentration 
correlated negatively with height Z-score (r = –0.39, 
p < 0.01), BMI Z-score (r = –0.34, p = 0.02), 
serum triglycerides (r = –0.37, p = 0.01), and serum 
uric acid (r = –0.31, p = 0.04). No statistically sig-
nificant correlations between vitamin D and other 
parameters of calcium-phosphorus metabolism were 
revealed (Table IV). Vitamin D did not correlate 
significantly with office blood pressure, ambulatory 
blood pressure and ABPM-derived blood pressure 
indices (blood pressure load, blood pressure variabi-
lity, blood pressure dipping, and ambulatory arterial 
stiffness index) (Table V). We found only a negative 
correlation between vitamin D concentration and 
mean 24-hour heart rate (r = –0.38, p < 0.01) with-
out significant relation between vitamin D and age 
(r = –0.22, p = 0.12). 
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Twenty-four out of 49 children (49.0%) were 
treated with antihypertensive medications during 
evaluation of vitamin D status. In this subgroup 
there were 18 boys and 6 girls, and mean age of this 
cohort was 14.68 ± 3.13 years. Mean duration of 
hypertension was 23.54 ± 21.65 months and was 
significantly longer compared to 25 not-treated pa-
tients (14.59 ± 18.57 months, p = 0.02). The treated 
and not treated children did not differ in terms of 
clinical and biochemical parameters and in ABPM 
parameters including AASI (0.384 ± 0.095 vs. 0.373 
± 0.139, p = 0.58). Following antihypertensive med-
ications were used in these 24 patients: calcium chan-
nel blockers in 18 (75.0%), angiotensin converting 
enzyme inhibitors in 12 (50.0%), angiotensin re-
ceptor blockers in 2 (8.3%), diuretics, beta- and 
alpha-adrenolytics, each in one (4.2%) patient. In 
this subgroup of 24 children we found a positive cor-
relation between ambulatory arterial stiffness index 
and vitamin D status (r = 0.50, p = 0.04).
Discussion
Our results revealed that both vitamin D deficiency 
and vitamin D suboptimal concentration are abun-
dant among paediatric patients with primary hy-
pertension. Only 3 patients had adequate or high 
supply of vitamin D. Our results are in consistence 
with other epidemiological studies assessing vitamin 
D in Polish children [7, 8]. Also, very similarly to 
our results, Płudowski [16] found 25(OH)D levels 
lower than 30 ng/mL in 91%, and lower than 20 ng/ 
/mL in 71% of paediatric patients with primary 
hypertension. 
In our cohort risk factors for low vitamin D sta-
tus were autumn-winter period, short stature, high 
BMI, hypertriglyceridaemia, and higher uricaemia. 
Decreased vitamin D concentration in autumn and 
winter is a consequence of diminished skin production 
of cholecalciferol from 7-dehydrocholesterol [5, 6]. 
Severe vitamin D deficiency leads to rickets with 
negative impact on height but the impact of mod-
erately lowered vitamin D level in adolescents on 
final height remains unclear [21]. The negative rela-
tion between 25(OH)D status and BMI is consistent 
with results of studies by Turer [22], Kao [17], and 
Płudowski [16]. According to Polish guidelines, both 
short stature and obesity are conditions associated 
with risk for vitamin D deficiency and indications 
for assessment of vitamin D status [5].
In case of vitamin D deficiency, initially, a com-
pensatory increase of PTH secretion to sustain nor-
mocalcaemia is observed. However, a resistance to 
Figure 1. Vitamin D status in children and adolescents with primary 
arterial hypertension: spring-summer and autumn-winter period (A), 
boys and girls (B), and patient treated and not treated with antihy-
pertensive medications (C)
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Table IV. Correlations of vitamin D concentration with parameters of calcium-phosphorus metabolism
Parameter r p
Serum calcium [mg/dL] r = -0.09 p = 0.57
Serum phosphorus [mg/dL] r = 0.00 p = 1.00
Calcium phosphorus product [mg2/dL2] r = 0.01 p = 0.95
Parathormone [ng/mL] r = -0.20 p = 0.19
Alkaline phosphatase [IU/L] r = 0.05 p = 0.73
Table V. Correlations of vitamin D concentration with office blood pressure and ambulatory blood pressure parameters
Parameter r p
Office blood pressure
SBP [mm Hg] r = –0.14 p = 0.33
SBP Z-score r = –0.15 p = 0.30
DBP [mm Hg] r = –0.19 p = 0.18
DBP Z-score r = –0.21 p = 0.15
Ambulatory blood pressure monitoring
SBP during 24h [mm Hg] r = –0.14 p = 0.34
DBP during 24h [mm Hg] r = –0.17 p = 0.25
MAP during 24h [mm Hg] r = –0.15 p = 0.29
MAP during 24h Z-score r = –0.23 p = 0.11
SBP load during 24h [%] r = –0.18 p = 0.21
DBP load during 24h [%] r = –0.13 p = 0.36
SBP variability r = –0.21 p = 0.14
DBP variability r = –0.23 p = 0.12
SBP dipping [%] r = –0.15 p = 0.30
DBP dipping [%] r = –0.21 p = 0.14
Ambulatory arterial stiffness index r = 0.26 p = 0.11
SBP — systolic blood pressure; DBP — diastolic blood pressure; MAP — mean arterial pressure
PTH may develop resulting in decreased calcium 
concentrations and increased phosphorus concentra-
tions and symptoms of hypocalcaemia together with 
osteopenia. When severity of vitamin D deficiency 
progresses, PTH resistance gets overcome leading to 
improved calcaemia but also to hypophosphataemia 
and clinical and radiological manifestation of rickets. 
Alkaline phosphatase increases, whereas 1,25(OH)2D 
is normal or increased. Finally, when vitamin D de-
ficiency becomes very severe, 1,25(OH)2D synthesis 
is inhibited with subsequent impairment of calcium 
and phosphorus absorption, along with persistent 
elevation of PTH [5, 21]. Interestingly, despite ex-
tremely common low levels of vitamin D we found 
no other abnormalities in calcium-phosphorus me-
tabolism in our cohort. Calcium, phosphorus, PTH, 
and alkaline phosphatase remained normal in all stud-
ied children. In addition, no significant correlation 
was found between 25(OH)D and these varia bles. 
In a study by Płudowski only a weak negative cor-
relation between parathormone and 25(OH)D was 
revealed (r = –0.24, p = 0.03) [16]. We hypothesize 
that negative findings of our study may be result of 
small sample size as we found trend towards high-
er PTH level in more vitamin D deficient subjects 
(r = –0.20, p = 0.19).
The fact that primary hypertension is more com-
monly seen in higher latitudes, and in those with 
deep skin pigmentation living far from the equator 
triggered speculations that vitamin D deficiency con-
tributes to increased prevalence of primary hyperten-
sion. Krause [10] treated adults with PH with UVB 
irradiation causing increase in 25(OH)D levels and 
drop in blood pressure in vitamin D-deficient indi-
viduals. This finding published already 20 years ago 
raised research interest in the relationship between 
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vitamin D and PH. Most of the cross-sectional studies 
showed an inverse relation between 25(OH)D status 
and systolic blood pressure or prevalence of primary 
hypertension [11, 12]. In addition, most prospective 
observational studies [13, 14] with observation pe-
riod up to 15 years [13] revealed increased risk for 
developing PH in case of vitamin D deficiency. 
Unfortunately, interventional trials on vitamin D 
supplementation in adults with arterial hypertension 
bring inconsistent results. Some studies show ben-
eficial impact of vitamin D supplementation [23], 
while other not [9]. Chen [6] states that inconsistent 
results of these trials were caused by short observa-
tion period and vitamin D supply not adjusted to 
actual vitamin D status. The ongoing prospective 
5-year VITAL study investigating impact of 2000 
IU/24h of cholecalciferol on cardiovascular morbid-
ity is hoped to bring final conclusions on this topic. 
In our study we found no significant relation be-
tween blood pressure measured both in office and in 
ABPM and vitamin D status. As blood pressure in 
paediatric population is dependent on anthropometric 
variables (especially height) [1, 2, 20] it is recommend-
ed to index measurements to normative values. When 
expressed as Z-score the relation was stronger but still 
did not reach statistical significance. Oscillometric 
devices measure directly mean arterial pressure and 
MAP during 24 hours seems to most precisely reflect 
cardiovascular burden as showed in ESCAPE study in 
children with chronic kidney disease [24]. We observed 
only a trend towards a negative correlation between 
MAP 24h and vitamin D status (r = –0.23, p = 0.11). 
We hypothesize that this relation might reflect findings 
from adult observational studies [11–14] and could 
become statistically significant in larger patient cohort.
Similarly, Płudowski [16] did not find differences 
in vitamin D status between prehypertension, stage 1 
hypertension, and stage 2 hypertension paediatric 
patients. On the other hand, in a study by Kao [6] 
lower vitamin D concentrations were related to both 
higher systolic and diastolic blood pressure in over-
weight and obese adolescents. Noteworthy, in con-
trast to our study, Kao [17] did not use ABPM, 
which more precisely reflects blood pressure com-
pared to office measurements.
Ambulatory arterial stiffness index is an ABPM- 
-derived marker of arterial compliance [4]. Its clin-
ical value in children remains unclear, though it 
was found to be elevated in children with hyperten-
sion [25] and IgA nephropathy [26]. In our cohort 
we observed a tendency towards positive correla-
tion between AASI and vitamin D status. When 
we analysed a subgroup of treated children, who 
were characterized by more severe hypertension and 
longer duration of hypertension, this relation became 
statistically significant. 
The relation between arterial stiffness and vita-
min D remains unclear. Experimental studies suggest 
that stimulation of vitamin D receptor (VDR) by 
1,25(OH)2D enhances nitric oxide production and 
decreases arterial stiffness [6, 15]. In adults both 
negative relation between arterial stiffness and vitamin 
D status was found [27] but also lower pulse wave 
velocity (PWV) in vitamin D deficient individuals 
was revealed [28]. In addition, both positive [29] and 
neutral [30] effect of vitamin D supplementation on 
arterial compliance was found. A negative relation be-
tween PWV and augmentation index and vitamin D 
was found in healthy adolescents [31], adolescents with 
diabetes mellitus [31] and children with chronic kid-
ney disease [32]. Also, contrary to our results, Turkish 
authors [33] found a negative relation (r = –0.385, 
p < 0.001) between vitamin D status and AASI in 
adults with newly diagnosed hypertensive adults. 
Limitation of our study is small patient sample 
which could have precluded disclosure of some rela-
tions between vitamin D and analysed parameters. 
We also did not evaluate 1,25(OH)2D concentration 
which is a direct stimulator of VDR in arterial wall 
and did not assess “golden standard” of arterial com-
pliance — pulse wave velocity. We are convinced that 
further studies on impact of vitamin D deficiency and 
vitamin D supplementation on development of arterial 
hypertension and arterial wall in children are necessary. 
Conclusions
1. Inadequate vitamin D supply is ubiquitous in 
children with arterial hypertension.
2. Vitamin D deficiency should be suspected espe-
cially in autumn-winter period and among obese 
and short children.
3. The relation between vitamin D status and ambu-
latory arterial stiffness index suggests negative in-
fluence of vitamin D on arterial wall but requires 
further investigations.
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